Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2025-04-03 Declaration of Voting R…
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Stimmrechtsmitteilung' (Voting Rights Notification) and explicitly deals with changes in share ownership percentages and total voting rights ('Anteil Stimmrechte', 'Gesamtstimmrechtsanteile') related to a specific individual (Friedrich von Bohlen und Halbach) and the company (Heidelberg Pharma AG). Section 2 indicates the reason for the notification is related to the 'Ausscheiden einer Partei aus einer Poolvereinbarung' (Exiting of a party from a pool agreement), which directly impacts voting rights disclosure. This type of mandatory disclosure regarding changes in significant shareholdings or voting power aligns perfectly with the definition of Major Shareholding Notification (MRQ). Although the header mentions 'Voting rights Announcements', the content is a formal notification of a change in voting rights percentage, which is captured by MRQ.
2025-04-03 German
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Regulatory Filings Classification · 100% confidence The document is a press release dated March 26, 2025, announcing that Heidelberg Pharma AG will present data from its ADC technology platforms at the AACR Annual Meeting 2025. It details the specific presentations (poster and talk) including abstract numbers, session titles, dates, and speakers. This type of announcement, focusing on participation in an external scientific conference and presentation of research findings, is best classified as a general corporate announcement or news release. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific investor presentation (IP) attached to the filing, and it is primarily disseminating news about scientific progress and conference attendance, the most appropriate category is Regulatory Filings (RNS) as a general corporate news item that doesn't fit the other specific categories, or potentially Investor Presentation (IP) if the content were the presentation itself, but here it is an announcement *about* presentations. Given the context of disseminating news about research updates and conference participation, RNS serves as the best general corporate news fallback, although it shares characteristics with IP content. However, since it is a press release announcing future presentations, RNS is the most suitable general category for non-financial, non-meeting specific corporate news.
2025-03-26 English
Annual financial report 2023/2024
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2024' and contains comprehensive sections including key figures, a letter to shareholders, a combined management report, consolidated financial statements, and an independent auditor's report. It provides detailed financial data and analysis for the fiscal year, fitting the definition of an Annual Report (10-K). FY 2024
2025-03-22 English
Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
Earnings Release Classification · 100% confidence The document explicitly states: 'Heidelberg Pharma today published its financial results and Annual Report for fiscal year 2024 (1 December 2023 – 30 November 2024)'. It contains detailed financial figures, key performance indicators, management commentary on the year's performance, and an outlook for the next year. This content aligns perfectly with the definition of a comprehensive annual financial report. Although it is presented as a press release announcing the publication, the document itself contains the substance of the annual financial results and report, making 'Annual Report (10-K)' the most appropriate classification for the content provided, rather than just a 'Report Publication Announcement (RPA)'. The length (over 21,000 characters) also supports this being the full report content, not just a brief announcement. FY 2024
2025-03-21 English
Annual financial report 2023/2024
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2024' and contains comprehensive sections including key figures, a letter to shareholders, a combined management report, consolidated financial statements, and an independent auditor's report. It provides detailed financial data and analysis for the fiscal year, fitting the definition of an Annual Report (10-K). FY 2024
2025-03-21 English
Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
Capital/Financing Update Classification · 98% confidence The document is a press release dated March 13, 2025, announcing an amendment to a royalty financing agreement between Heidelberg Pharma AG and HealthCare Royalty. It details financial terms, payments, and the extension of the company's cash runway. This type of announcement, concerning fundraising, financing activities, or capital structure changes (specifically a royalty financing amendment), directly aligns with the definition of 'Capital/Financing Update'. It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA).
2025-03-14 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.